iPSpine | Induced pluripotent stem cell-based therapy for spinal regeneration

Summary
Low back pain (LBP) is a leading cause of disability and morbidity worldwide. It is widely accepted that a major contributor to LBP is intervertebral disc degeneration (IDD). IDD account for at least 40% (~280 million) of all LBP cases, leading to an EU-economic burden of ~€240 billion. These patients receive conservative treatment (e.g. pain relief medication and physiotherapy). When the latter is unsatisfactory, the only option left are invasive and costly surgical intervention. To date, no treatments halt or reverse IDD. Despite the profound socioeconomic burden and impact of IDD, decreasing the quality of life of millions of people, a game-changing treatment strategy for IDD-induced LBP is almost non-existent. The iPSpine consortium was formed to initiate a European-led research effort to identify a future advanced therapeutic strategy that results into a radical new treatment of IDD-induced LBP. With their multi-disciplinary expertise in the development of advanced therapies and their translation from bench to bedside, the aim of the iPSpine team is to investigate and develop a new advanced therapy medicinal product (ATMP) of the future, based on a novel developmental biology-based therapeutic strategy employing pluripotent stem cells (iPSC) and smart biomaterials. The iPSpine consortium will develop and demonstrate Proof-of-concept with the aid of novel and extended knowledge, tools and technology platforms. Hereby, iPSpine has the ambition to make a significant contribution by reducing translational bottlenecks through open innovation and take European leadership in the development of ATMPs. The iPSpine impact: iPSpine seeks to offer novel technologies and ATMPs for the advanced therapy research and development community. IDD will be the showcase, offering improved quality of life for millions of patients with IDD-induced LBP, through long-lasting reduction of LBP, reduced LBP-related premature retirement, and improved socio-economic contribution.
Unfold all
/
Fold all
More information & hyperlinks
Web resources: https://cordis.europa.eu/project/id/825925
Start date: 01-01-2019
End date: 30-06-2024
Total budget - Public funding: 15 396 031,00 Euro - 14 959 781,00 Euro
Cordis data

Original description

Low back pain (LBP) is a leading cause of disability and morbidity worldwide. It is widely accepted that a major contributor to LBP is intervertebral disc degeneration (IDD). IDD account for at least 40% (~280 million) of all LBP cases, leading to an EU-economic burden of ~€240 billion. These patients receive conservative treatment (e.g. pain relief medication and physiotherapy). When the latter is unsatisfactory, the only option left are invasive and costly surgical intervention. To date, no treatments halt or reverse IDD. Despite the profound socioeconomic burden and impact of IDD, decreasing the quality of life of millions of people, a game-changing treatment strategy for IDD-induced LBP is almost non-existent. The iPSpine consortium was formed to initiate a European-led research effort to identify a future advanced therapeutic strategy that results into a radical new treatment of IDD-induced LBP. With their multi-disciplinary expertise in the development of advanced therapies and their translation from bench to bedside, the aim of the iPSpine team is to investigate and develop a new advanced therapy medicinal product (ATMP) of the future, based on a novel developmental biology-based therapeutic strategy employing pluripotent stem cells (iPSC) and smart biomaterials. The iPSpine consortium will develop and demonstrate Proof-of-concept with the aid of novel and extended knowledge, tools and technology platforms. Hereby, iPSpine has the ambition to make a significant contribution by reducing translational bottlenecks through open innovation and take European leadership in the development of ATMPs. The iPSpine impact: iPSpine seeks to offer novel technologies and ATMPs for the advanced therapy research and development community. IDD will be the showcase, offering improved quality of life for millions of patients with IDD-induced LBP, through long-lasting reduction of LBP, reduced LBP-related premature retirement, and improved socio-economic contribution.

Status

SIGNED

Call topic

SC1-BHC-09-2018

Update Date

26-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.3. Treating and managing disease
H2020-EU.3.1.3.0. Cross-cutting call topics
H2020-SC1-2018-Single-Stage-RTD
SC1-BHC-09-2018 Innovation platforms for advanced therapies of the future